CLAVASEPTIN 250MG X 10TB

Description
Clavaseptin 250 mg 10 tablets

Chewable tablets against infections in dogs and cats

Indications:

Dogs:

For the treatment of gingivitis associated with periodontal infections caused by amoxicillin/clavulanic acid-sensitive bacteria.
For the treatment of skin and soft tissues, such as wounds and abscesses, caused by sensitive bacteria strains of Pasteurella spp., Staphylococcus spp.. and Streptococcus spp..
Note: To limit the development of antimicrobial resistance this medicinal product should be used as directed It is recommended to obtain culture samples and sensitivity testing prior to in vitro treatment.

Active Ingredients (Per Tablet)

Amoxicillin (as amoxicillin trihydrate) 400 mg
Clavulanic acid (as clavulanate potassium) 100 mg
For veterinary use ONLY.

Form of administration:

Divisible tablets. Clavaseptin chewable tablets (500 mg)

Method of administration

The recommended dose of amoxicillin/clavulanic acid is 12.5 mg/kg body weight twice daily, orally in dogs and cats.
Dogs – periodontal infections must be treated for 7 days.
Taste: In palatability studies, 75% of cats and 50% of dogs offered a Clavaseptin 50 mg/62.5 mg/250 mg/500 mg in an empty food bowl spontaneously eaten within 5 minutes (no human stimulation).

Contraindications:

Do not use in cases with a history of penicillin or cephalosporin hypersensitivity.

ATTENSION:

The safety of Clavaseptin 50 mg/62.5 mg/250 mg/500 mg has not been established during pregnancy, lactation, and in breeding animals.
Laboratory studies in rats have not demonstrated teratogenic, fetotoxic, or maternotoxic effects.
In case of anaphylaxis, administer epinephrine and/or steroids.

Warning: Keep out of reach of children.

Side effects: Vomiting and diarrhea may be observed.

Treatment may be continued depending on the severity of the observed side effect, as determined by the treating veterinarian.
Hypersensitivity reactions (allergic skin reactions, anaphylaxis) are rarely observed.
In such cases, administration should be discontinued and symptomatic treatment given.

Pharmacology

Amoxicillin is an aminobenzylpenicillin from the β-lactam penicillin family that prevents bacterial cell wall formation by interfering with the final step of peptidoglycan synthesis.
Clavulanic acid is an inhibitor of intracellular and extracellular β-lactamases that protects amoxicillin from inactivation by multiple β-lactamases.
Amoxicillin/clavulanate has a wide range of activities that includes β-lactamase strains producing both gram-positive and Gram-negative, facultative anaerobic and obligate anaerobics.
The amoxicillin clavulanic acid combination has demonstrated in vitro activity against Pasteurella spp.., Staphylococcus spp.. and Streptococcus spp.. isolated from cats with skin and soft tissue infections and from a wide range of aerobic and anaerobic Gram-positive and Gram-negative bacteria associated with gingivitis in dogs. Isolate of Pseudomonas spp.. have generally been shown to be resistant in vitro to amoxicillin/clavulanic acid.

After oral administration at the recommended dose in dogs and cats, the absorption of amoxicillin and clavulanic acid is rapid.
In dogs, the maximum plasma concentration of amoxicillin is reached in 1.5 pg/ml in 1.4 h and the maximum plasma concentration of clavulanic acid of 0.9 pg/ml is reached in 0.9 hours.